Is ResMed Inc. (RMD) A Good Stock To Buy Now?

Billion Photos/Shutterstock.com

ResMed is simply a starring planetary slumber apnea attraction institution that the marketplace has precocious mispriced owed to fears astir GLP-1 weight-loss drugs disrupting its halfway therapy demand. Despite the narrative, ResMed continues to run successful a structural request marketplace with an estimated 936 cardinal slumber apnea patients globally, a basal that is improbable to beryllium meaningfully reduced successful the foreseeable future.

Read More: 15 AI Stocks That Are Quietly Making Investors Rich

Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

The company’s halfway spot lies successful its consumables business, wherever masks, tubes and headgear are replaced each ninety days nether security reimbursement cycles, creating highly predictable and recurring gross streams. This conception generates gross margins supra 60 percent and remains resilient due to the fact that the underlying information is anatomical, meaning adjacent patients utilizing GLP-1 drugs often inactive necessitate CPAP therapy for residual apnea.

ResMed’s AirView connected attraction level further strengthens its moat, linking astir 20 2 cardinal devices and providing payers with compliance information that reduces hospitalizations and improves attraction ratio crossed the ecosystem. The expanding standard of this information web enhances switching costs and embeds ResMed deeper into payer and supplier workflows, reinforcing semipermanent recurring gross visibility.

Financially, ResMed generates astir 2.2 cardinal dollars successful yearly escaped currency flow, reflecting the durability of its exemplary and beardown operating leverage. Despite this strength, the banal has been nether unit for 2 years owed to GLP-1 driven concerns that person not been reflected successful existent fundamentals. At existent levels, ResMed trades astatine a discount to its humanities 30x-plus prime multiple, offering a compelling semipermanent re-rating accidental arsenic fears normalize implicit clip unwinds.

Previously, we covered a bullish thesis connected ResMed Inc. (RMD) by LongTermValue Research successful April 2025, which highlighted the company’s beardown slumber apnea request and maturation outlook. RMD’s banal terms has depreciated by astir 11.68% since our coverage. Variant_Invest shares a akin presumption but emphasizes GLP-1 fears arsenic overblown and highlights consumables and AirView information level arsenic cardinal recurring gross and moat drivers supporting semipermanent compounding.